Stephanie Guseh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephanie Guseh has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Louise Wilkins-Haug
Division of Maternal‐Fetal Medicine and Reproductive Genetics Brigham and Women's Hospital Boston Massachusetts USA
5 shared publications - Kathryn J. Gray
Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA
3 shared publications - Sophie Adams
Department of Maternal Fetal Medicine Brigham and Women's Hospital Boston Massachusetts USA
3 shared publications - Hannah Llorin
LMND Medical Group San Francisco California USA
2 shared publications Judith Foster
Division of Maternal‐Fetal Medicine Newton Wellesley Hospital Harvard Medical School Boston Massachusetts USA
2 shared publicationsLori J. Dobson
Center for Fetal Medicine and Reproductive Genetics Department of Obstetrics and Gynecology Brigham and Women's Hospital Boston Massachusetts USA
2 shared publications
Latest Publications
- 19 May 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (10) , 1598-1606
Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing
Objectives: We evaluated the diagnostic yield of karyotype (KT) and chromosomal microarray (CMA) with isolated severe FGR diagnosed before 32 weeks' gestation. Exome and genome sequencing (ES/GS) level data were available in a subset of this population. Method: We performed a retrospective review of singleton pregnancies (delivered 2022–2025) with estimated fetal weight or abdominal circumference < 3rd percentile before 32 weeks' gestation, no sonographic structural anomalies, and diagnostic testing (KT, CMA, ES, or GS) via amniocentesis or cord blood. Cases with abnormal cell‐free DNA were excluded. Results: Forty cases were included (mean diagnosis 26.8 weeks). Testing was performed via amniocentesis in 42% and cord blood in 58%. All KT (27/40) were normal. CMA (39/40) identified one pathogenic CNV (2.5%) and three (7.5%) variants of uncertain significance (VUS). Four (10%) showed ≥ 1 region of absence of heterozygosity (AOH) > 10Mb; one revealed maternal uniparental disomy of chromosome 6. Sequencing ( N = 10) detected one VUS in COL1A1 . Acute viral infection was not observed in any of the cases. Conclusions: CMA was diagnostic in 2/39 (5.1%) cases, a pathogenic CNV implicating the SHOX gene, and maternal UPD 6, which were consistent with FGR. There was a remarkable rate (10%) of AOH. Further investigation, including placental studies and genome sequencing, may elucidate whether AOH is a contributing factor for FGR.
- 19 May 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (10) , 1598-1606
Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing
Objectives: We evaluated the diagnostic yield of karyotype (KT) and chromosomal microarray (CMA) with isolated severe FGR diagnosed before 32 weeks' gestation. Exome and genome sequencing (ES/GS) level data were available in a subset of this population. Method: We performed a retrospective review of singleton pregnancies (delivered 2022–2025) with estimated fetal weight or abdominal circumference < 3rd percentile before 32 weeks' gestation, no sonographic structural anomalies, and diagnostic testing (KT, CMA, ES, or GS) via amniocentesis or cord blood. Cases with abnormal cell‐free DNA were excluded. Results: Forty cases were included (mean diagnosis 26.8 weeks). Testing was performed via amniocentesis in 42% and cord blood in 58%. All KT (27/40) were normal. CMA (39/40) identified one pathogenic CNV (2.5%) and three (7.5%) variants of uncertain significance (VUS). Four (10%) showed ≥ 1 region of absence of heterozygosity (AOH) > 10Mb; one revealed maternal uniparental disomy of chromosome 6. Sequencing ( N = 10) detected one VUS in COL1A1 . Acute viral infection was not observed in any of the cases. Conclusions: CMA was diagnostic in 2/39 (5.1%) cases, a pathogenic CNV implicating the SHOX gene, and maternal UPD 6, which were consistent with FGR. There was a remarkable rate (10%) of AOH. Further investigation, including placental studies and genome sequencing, may elucidate whether AOH is a contributing factor for FGR.
- 20 May 2024
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (6-7) , 733-738
Transforming congenital heart disease management: Advances in fetal cardiac interventions
This review addresses the transformative advancements in fetal cardiac interventions (FCI) for congenital heart diseases (CHD), with a particular focus on aortic stenosis with evolving hypoplastic left heart syndrome, pulmonary atresia with an intact ventricular septum, and HLHS with an intact atrial septum (HLHS‐IAS). We outline the specific FCI techniques employed, the refined criteria for selecting appropriate fetal and maternal candidates, and the promising yet varied outcomes associated with these procedures. Procedural strategies and clinical decision‐making are examined as we take into account the fetal pathophysiology and the benefits and risks of early intervention. We highlight the role of multidisciplinary teams in improving technical success and managing immediate procedural complications, which have led to significant improvements in procedural outcomes. Additionally, the review discusses the long‐term outcomes, challenges, and future research directions in FCI, emphasizing the necessity for continuous innovation and collaboration across specialties to advance the management of CHD. The integration of new technologies and research findings holds the promise of further enhancing FCI success rates and patient outcomes.
- 20 May 2024
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (6-7) , 733-738
Transforming congenital heart disease management: Advances in fetal cardiac interventions
This review addresses the transformative advancements in fetal cardiac interventions (FCI) for congenital heart diseases (CHD), with a particular focus on aortic stenosis with evolving hypoplastic left heart syndrome, pulmonary atresia with an intact ventricular septum, and HLHS with an intact atrial septum (HLHS‐IAS). We outline the specific FCI techniques employed, the refined criteria for selecting appropriate fetal and maternal candidates, and the promising yet varied outcomes associated with these procedures. Procedural strategies and clinical decision‐making are examined as we take into account the fetal pathophysiology and the benefits and risks of early intervention. We highlight the role of multidisciplinary teams in improving technical success and managing immediate procedural complications, which have led to significant improvements in procedural outcomes. Additionally, the review discusses the long‐term outcomes, challenges, and future research directions in FCI, emphasizing the necessity for continuous innovation and collaboration across specialties to advance the management of CHD. The integration of new technologies and research findings holds the promise of further enhancing FCI success rates and patient outcomes.
- 18 April 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (9) , 1120-1131
Postnatal genetic testing on cord blood for prenatally identified high‐probability cases
Objective: To evaluate the utility of postnatal genetic testing on umbilical cord blood (CB) for prenatally identified high‐probability fetuses.Method: CB for genetic testing was offered to individuals who met one of the following criteria: (i) fetal anomaly, (ii) positive non‐invasive prenatal screening by cfDNA or biochemical analysis, or (iii) family history. Individuals with diagnostic testing, but not microarray, were also included when recommended by society guidelines. CB was collected at Brigham and Women's and Emerson Hospitals between 2016 and 2021.Results: 448 individuals consented for cord blood testing (370 (82.6%) for fetal anomalies, 51 (11.4%) for high‐probability cfDNA, and 27 (6.0%) for family history) and a total of 393 (87.7%) samples were analyzed. Genetic testing yielded a diagnosis in 92 (23.4%) neonates by karyotype (n = 37), chromosomal microarray (CMA) (n = 32), and other molecular analysis (n = 23). Testing averaged 10.3 days (range 1–118 days). 68 (73.9%) diagnoses potentially impacted neonatal management. MCC could not be definitively excluded in only 1.4% (6/418) of samples.Conclusion: Prenatal identification of high‐probability fetuses and genetic testing on CB facilitates timely genetic diagnoses and neonatal management. Testing provides reassurance and reduces a postnatal diagnostic odyssey for high‐probability neonates.
- 18 April 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (9) , 1120-1131
Postnatal genetic testing on cord blood for prenatally identified high‐probability cases
Objective: To evaluate the utility of postnatal genetic testing on umbilical cord blood (CB) for prenatally identified high‐probability fetuses.Method: CB for genetic testing was offered to individuals who met one of the following criteria: (i) fetal anomaly, (ii) positive non‐invasive prenatal screening by cfDNA or biochemical analysis, or (iii) family history. Individuals with diagnostic testing, but not microarray, were also included when recommended by society guidelines. CB was collected at Brigham and Women's and Emerson Hospitals between 2016 and 2021.Results: 448 individuals consented for cord blood testing (370 (82.6%) for fetal anomalies, 51 (11.4%) for high‐probability cfDNA, and 27 (6.0%) for family history) and a total of 393 (87.7%) samples were analyzed. Genetic testing yielded a diagnosis in 92 (23.4%) neonates by karyotype (n = 37), chromosomal microarray (CMA) (n = 32), and other molecular analysis (n = 23). Testing averaged 10.3 days (range 1–118 days). 68 (73.9%) diagnoses potentially impacted neonatal management. MCC could not be definitively excluded in only 1.4% (6/418) of samples.Conclusion: Prenatal identification of high‐probability fetuses and genetic testing on CB facilitates timely genetic diagnoses and neonatal management. Testing provides reassurance and reduces a postnatal diagnostic odyssey for high‐probability neonates.
- 16 April 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (9) , 1110-1119
Single gene non‐invasive prenatal screening for autosomal dominant conditions in a high‐risk cohort
Purpose: To determine the utility of single gene non‐invasive prenatal screening (NIPS‐SGD) in a high‐risk reproductive genetics clinic.Methods: A clinical pilot for NIPS‐SGD was conducted from March 2020 to November 2021. A NIPS‐SGD panel assessing pathogenic variants in 30 genes was offered to pregnant individuals for the following indications: (1) advanced sperm age ≥40 years, (2) nuchal translucency (NT) ≥ 3.5 mm, (3) fetal anomaly, or (4) family history of a condition covered by the panel. Diagnostic testing was offered concurrently.Results: NIPS‐SGD was ordered for 253 individuals: 88 (34.8%) for fetal anomalies, 96 (37.9%) for advanced sperm age, 37 (14.6%) for increased NT, and 5 (2.0%) for family history. Among 228 (90.1%) completed tests, 8 (3.5%) were positive. Diagnostic testing for 78 individuals revealed no false positive or negative results. Of 41 (25.9%) individuals who received a molecular diagnosis, 34 (82.9%) were outside the scope of NIPS‐SGD. Positive NIPS‐SGD altered medical management in five cases.Conclusions: NIPS‐SGD in a high‐risk population can lead to earlier prenatal diagnosis, enhanced surveillance, and targeted genetic analysis, but should not replace clinically indicated diagnostic testing. Potential incidental findings include parental diagnoses and misattributed parentage.
- 16 April 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (9) , 1110-1119
Single gene non‐invasive prenatal screening for autosomal dominant conditions in a high‐risk cohort
Purpose: To determine the utility of single gene non‐invasive prenatal screening (NIPS‐SGD) in a high‐risk reproductive genetics clinic.Methods: A clinical pilot for NIPS‐SGD was conducted from March 2020 to November 2021. A NIPS‐SGD panel assessing pathogenic variants in 30 genes was offered to pregnant individuals for the following indications: (1) advanced sperm age ≥40 years, (2) nuchal translucency (NT) ≥ 3.5 mm, (3) fetal anomaly, or (4) family history of a condition covered by the panel. Diagnostic testing was offered concurrently.Results: NIPS‐SGD was ordered for 253 individuals: 88 (34.8%) for fetal anomalies, 96 (37.9%) for advanced sperm age, 37 (14.6%) for increased NT, and 5 (2.0%) for family history. Among 228 (90.1%) completed tests, 8 (3.5%) were positive. Diagnostic testing for 78 individuals revealed no false positive or negative results. Of 41 (25.9%) individuals who received a molecular diagnosis, 34 (82.9%) were outside the scope of NIPS‐SGD. Positive NIPS‐SGD altered medical management in five cases.Conclusions: NIPS‐SGD in a high‐risk population can lead to earlier prenatal diagnosis, enhanced surveillance, and targeted genetic analysis, but should not replace clinically indicated diagnostic testing. Potential incidental findings include parental diagnoses and misattributed parentage.
- 24 August 2021
- Published by Wiley in Prenatal Diagnosis
- Vol. 41 (11) , 1460-1466
Counseling for personal health implications identified during reproductive genetic carrier screening
Objective: Preconception and prenatal carrier screening is designed to provide reproductive risk information, but carriers for some autosomal recessive or X‐linked conditions also have personal health risks. This study investigated the prevalence of and inclusion of personal health implications in pre‐ and post‐test counseling.Methods: Twelve genetic conditions with personal health risks for carriers included on carrier screening panels but not otherwise screened routinely were identified (e.g., Gaucher disease with Parkinson's disease risk). A retrospective review was performed of patients with a positive carrier screen for one of these conditions at our center from 2012 to 2019.Results: Of 6147 individuals that had carrier screening for one of the twelve conditions, 96 (1.56%) did not report a known family history and screened positive for one of the conditions. Testing was ordered largely by reproductive endocrinologists (51.0%) and genetic counselors (35.4%). Most individuals did not receive pre‐ (96.8%) or post‐test (64.6%) counseling about personal health risks. Post‐test counseling was performed principally by genetic counselors (97.1%). For carriers of conditions with guidelines for specialist referral, most individuals (75.9%) were referred.Conclusion: Expanded genetic carrier screening increasingly identifies individuals with personal health implications, but patients are frequently not counseled before or after testing. These findings stress the importance of developing guidelines for practitioners about expanded carrier screening counseling and follow‐up.
- 24 August 2021
- Published by Wiley in Prenatal Diagnosis
- Vol. 41 (11) , 1460-1466
Counseling for personal health implications identified during reproductive genetic carrier screening
Objective: Preconception and prenatal carrier screening is designed to provide reproductive risk information, but carriers for some autosomal recessive or X‐linked conditions also have personal health risks. This study investigated the prevalence of and inclusion of personal health implications in pre‐ and post‐test counseling.Methods: Twelve genetic conditions with personal health risks for carriers included on carrier screening panels but not otherwise screened routinely were identified (e.g., Gaucher disease with Parkinson's disease risk). A retrospective review was performed of patients with a positive carrier screen for one of these conditions at our center from 2012 to 2019.Results: Of 6147 individuals that had carrier screening for one of the twelve conditions, 96 (1.56%) did not report a known family history and screened positive for one of the conditions. Testing was ordered largely by reproductive endocrinologists (51.0%) and genetic counselors (35.4%). Most individuals did not receive pre‐ (96.8%) or post‐test (64.6%) counseling about personal health risks. Post‐test counseling was performed principally by genetic counselors (97.1%). For carriers of conditions with guidelines for specialist referral, most individuals (75.9%) were referred.Conclusion: Expanded genetic carrier screening increasingly identifies individuals with personal health implications, but patients are frequently not counseled before or after testing. These findings stress the importance of developing guidelines for practitioners about expanded carrier screening counseling and follow‐up.
- 1 July 2021
- Published by Elsevier in Genetics in Medicine
- Vol. 23 (7) , 1341-1348
Utility of noninvasive genome-wide screening: a prospective cohort of obstetric patients undergoing diagnostic testing
- 1 July 2021
- Published by Elsevier in Genetics in Medicine
- Vol. 23 (7) , 1341-1348
Utility of noninvasive genome-wide screening: a prospective cohort of obstetric patients undergoing diagnostic testing
- 1 March 2021
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 76 (3) , 129-131
Gene and Stem Cell Therapies for Fetal Care: A Review
(Abstracted from JAMA Pediatr 2020;174(10):985–991) In utero stem cell transplantation and gene therapy have the ability to cure and treat many different genetic disorders in children and adults. For some conditions, this could be applied before birth and allow for better outcomes, as well as reduce the financial burden put on families with children with genetic disorders.
- 1 March 2021
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 76 (3) , 129-131
Gene and Stem Cell Therapies for Fetal Care: A Review
(Abstracted from JAMA Pediatr 2020;174(10):985–991) In utero stem cell transplantation and gene therapy have the ability to cure and treat many different genetic disorders in children and adults. For some conditions, this could be applied before birth and allow for better outcomes, as well as reduce the financial burden put on families with children with genetic disorders.
- 24 December 2019
- Published by Wiley in Prenatal Diagnosis
- Vol. 40 (4) , 415-423
Fetal cardiac intervention—Perspectives from a single center
Fetal cardiac intervention was first proposed in the early 1990s to impact cardiac development and survival of fetuses with fetal aortic stenosis and evolving hypoplastic left heart syndrome (HLHS). Although initial attempts of fetal aortic valvuloplasty were unsuccessful and carried a high rate of morbidity and mortality, our collaborative group at the Brigham and Women's Hospital and Boston Children's Hospital have reinvigorated the procedure using improvements in imaging, anesthesia, balloon catheters, and surgical techniques. Two decades of experience have now allowed us to document the safety of in utero intervention and to achieve a better understanding of the impact of midgestation intervention on developing HLHS. Research into underlying genetics, predictive biomarkers, and ways to incorporate stem cell technology will hopefully allow us to further refine the procedure to most benefit children with this historically lethal disease.
- 24 December 2019
- Published by Wiley in Prenatal Diagnosis
- Vol. 40 (4) , 415-423
Fetal cardiac intervention—Perspectives from a single center
Fetal cardiac intervention was first proposed in the early 1990s to impact cardiac development and survival of fetuses with fetal aortic stenosis and evolving hypoplastic left heart syndrome (HLHS). Although initial attempts of fetal aortic valvuloplasty were unsuccessful and carried a high rate of morbidity and mortality, our collaborative group at the Brigham and Women's Hospital and Boston Children's Hospital have reinvigorated the procedure using improvements in imaging, anesthesia, balloon catheters, and surgical techniques. Two decades of experience have now allowed us to document the safety of in utero intervention and to achieve a better understanding of the impact of midgestation intervention on developing HLHS. Research into underlying genetics, predictive biomarkers, and ways to incorporate stem cell technology will hopefully allow us to further refine the procedure to most benefit children with this historically lethal disease.
- 25 September 2019
- Published by Springer Nature in Human Genetics
- Vol. 139 (9) , 1141-1148
Noninvasive prenatal testing: from aneuploidy to single genes
Noninvasive prenatal testing has undergone rapid advances in the last few years. Although researchers have long known about circulating pregnancy-based cell-free fragments of DNA in maternal plasma, it was the introduction of massively parallel sequencing that allowed noninvasive prenatal testing to become a widely used clinical test. This review will begin with an in-depth analysis of the use of noninvasive prenatal testing for aneuploidy, including common causes for inaccurate and/or discordant results. It will also review the ongoing expansion of noninvasive prenatal testing to include copy number variants and select single-gene disorders. Finally, integrated throughout the review is a comparison of noninvasive prenatal testing to more traditional screening methods along with some medical and ethical implications of the widespread use of this new technology.
- 25 September 2019
- Published by Springer Nature in Human Genetics
- Vol. 139 (9) , 1141-1148
Noninvasive prenatal testing: from aneuploidy to single genes
Noninvasive prenatal testing has undergone rapid advances in the last few years. Although researchers have long known about circulating pregnancy-based cell-free fragments of DNA in maternal plasma, it was the introduction of massively parallel sequencing that allowed noninvasive prenatal testing to become a widely used clinical test. This review will begin with an in-depth analysis of the use of noninvasive prenatal testing for aneuploidy, including common causes for inaccurate and/or discordant results. It will also review the ongoing expansion of noninvasive prenatal testing to include copy number variants and select single-gene disorders. Finally, integrated throughout the review is a comparison of noninvasive prenatal testing to more traditional screening methods along with some medical and ethical implications of the widespread use of this new technology.
- 1 June 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (7) , 640-646
Antepartum management and obstetric outcomes among pregnancies with Down syndrome from diagnosis to delivery
Objective: Little is known about the obstetric care of an ongoing pregnancy with trisomy 21. We sought to ascertain an obstetric profile for pregnancies with Down syndrome to help guide prenatal management.Method: Pregnancies managed for delivery with trisomy 21 between 2003 and 2014 were analyzed. We reviewed demographic data, diagnostic testing, prenatal surveillance, obstetric outcomes, and placental pathology. T‐test, chi‐squared test, and Fisher correction were used as indicated.Results: Sixty‐eight pregnancies were identified, and four women (5.9%) experienced a loss during the pregnancy. Among the remaining 64 pregnancies, the average gestational age at delivery was 36.9 weeks, growth restriction was present in 12 (17.5%), and major anomalies were present in 51 (75.0%). Delivery was undertaken for non‐reassuring fetal surveillance in 35.9% of the pregnancies; 93% of which represented a change from prior reassuring surveillance and 52.6% of which demonstrated histopathologic evidence of placental insufficiency. None among increased maternal age, the presence of an anomaly, or growth restriction were significantly more common in the group with non‐reassuring surveillance.Conclusion: There are high rates of fetal growth restriction, delivery for non‐reassuring fetal status, and evidence of placental insufficiency among affected pregnancies, suggesting a role for antepartum surveillance. © 2017 John Wiley & Sons, Ltd.
- 1 June 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (7) , 640-646
Antepartum management and obstetric outcomes among pregnancies with Down syndrome from diagnosis to delivery
Objective: Little is known about the obstetric care of an ongoing pregnancy with trisomy 21. We sought to ascertain an obstetric profile for pregnancies with Down syndrome to help guide prenatal management.Method: Pregnancies managed for delivery with trisomy 21 between 2003 and 2014 were analyzed. We reviewed demographic data, diagnostic testing, prenatal surveillance, obstetric outcomes, and placental pathology. T‐test, chi‐squared test, and Fisher correction were used as indicated.Results: Sixty‐eight pregnancies were identified, and four women (5.9%) experienced a loss during the pregnancy. Among the remaining 64 pregnancies, the average gestational age at delivery was 36.9 weeks, growth restriction was present in 12 (17.5%), and major anomalies were present in 51 (75.0%). Delivery was undertaken for non‐reassuring fetal surveillance in 35.9% of the pregnancies; 93% of which represented a change from prior reassuring surveillance and 52.6% of which demonstrated histopathologic evidence of placental insufficiency. None among increased maternal age, the presence of an anomaly, or growth restriction were significantly more common in the group with non‐reassuring surveillance.Conclusion: There are high rates of fetal growth restriction, delivery for non‐reassuring fetal status, and evidence of placental insufficiency among affected pregnancies, suggesting a role for antepartum surveillance. © 2017 John Wiley & Sons, Ltd.